Learning from COVID-19: How drug hunters can prepare for the next pandemic

Drug Discov Today. 2023 Jul 21:103723. doi: 10.1016/j.drudis.2023.103723. Online ahead of print.ABSTRACTOver 3 years, the SARS-CoV-2 pandemic killed nearly 7 million people and infected more than 767 million globally. During this time, our very small company was able to contribute to antiviral drug discovery efforts through global collaborations with other researchers, which enabled the identification and repurposing of multiple molecules with activity against SARS-CoV-2 including pyronaridine tetraphosphate, tilorone, quinacrine, vandetanib, lumefantrine, cetylpyridinium chloride, raloxifene, carvedilol, olmutinib, dacomitinib, crizotinib, and bosutinib. We highlight some of the key findings from this experience of using different computational and experimental strategies, and detail some of the challenges and strategies for how we might better prepare for the next pandemic so that potential antiviral treatments are available for future outbreaks. Teaser: Through global collaborations, a very small company was able to identify computationally and experimentally numerous small molecules with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approaches may be instructive for future antiviral drug discovery efforts.PMID:37482237 | DOI:10.1016/j.drudis.2023.103723
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research